NIH partners with 11 leading Pharmas on development of new cancer immunotherapy strategies

13 October 2017

Leading US pharma companies, as well as several based in Europe, are collaborating with the USA’s National Institutes of Health (NIH) in a partnership to accelerate cancer research.

Along with the 11 leading biopharmaceutical companies, the NIH today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.

The National Immunotherapy Coalition (NIC), a Cancer Moonshot 2020 initiative, was launched at the annual JP Morgan Healthcare Conference in San Francisco in January 2016. Under the Obama administration, then US Vice President, Joseph Biden, became the head of the campaign.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK